Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors.

about

Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors.

Item

http://www.wikidata.org/entity/Q50206074

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@en

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@nl

type

Item

label

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@en

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@nl

prefLabel

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@en

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@nl

P1476

Additional Benefits of Routine ...... n, and Proton Pump Inhibitors.

@en

P2093

Hoon Jai Chun

http://www.w3.org/2001/XMLSchema#string

Jong-Jae Park

http://www.w3.org/2001/XMLSchema#string

Moon Kyung Joo

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-Analysis

Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

Statins and the risk of colorectal cancer

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study

Chronic proton pump inhibitor therapy and the risk of colorectal cancer

STATs in cancer inflammation and immunity: a leading role for STAT3

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

P304

1-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000480149

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28881340

http://www.w3.org/2001/XMLSchema#string

P921

metformin